ASH Annual Meeting and Exposition | Conference

Asciminib Induces Deeper and Prolonged Molecular Responses in Chronic-Phase CML

December 12th 2021

Asciminib demonstrated a consistent improvement in major molecular response rate and depth of response vs bosutinib in patients with chronic-phase chronic myeloid leukemia without any new or worsening adverse effects.

Ibrutinib Plus R-Mini-CHOP Misses OS End Point but Shows Improved PFS in Newly Diagnosed DLBCL

December 12th 2021

Ibrutinib plus rituximab and mini-CHOP failed to demonstrate a statistically significant improvement in overall survival at 2 years but led to an improvement in progression-free survival, quality of life, and function in elderly patients with diffuse large B-cell lymphoma.

Acalabrutinib Provides Long-Term Survival Benefits Vs. Standard of Care in Relapsed/Refractory Chronic Lymphocytic Leukemia

December 12th 2021

Treatment with acalabrutinib for relapsed/refractory chronic lymphocytic leukemia was effective out to 3 years and demonstrated a progression-free survival benefit over standard of care, according to 3-year follow-up of the ASCEND study.

Frontline and Continuous Treatment With Ibrutinib Plus Rituximab Improves Quality of Life in Patients With CLL

December 12th 2021

Quality of life improved in patients with chronic lymphocytic leukemia when treated in the frontline setting with ibrutinib-rituximab and with fludarabine, cyclophosphamide, and rituximab. Improved quality of life was also maintained during continuous therapy with ibrutinib and did not decline over time.

Real-World Efficacy of Tisagenlecleucel in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Similar to Clinical Trial Data With Improved Safety Outcomes

December 12th 2021

Real-world data of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia treated with tisagenlecleucel demonstrated similar efficacy outcomes and a more favorable safety profile compared with the ELIANA trial.

Selinexor Plus D-Vd Shows Promising Results and Safety in Patients With Relapsed or Refractory Multiple Myeloma

December 12th 2021

Selinexor in combination with daratumumab, bortezomib and dexamethasone demonstrated a manageable safety profile and encouraging efficacy in patients with late- and early-relapsed multiple myeloma.

Ponatinib Elicits Encouraging Activity in TKI-Resistant CP-CML

December 12th 2021

Ponatinib demonstrated high response rates in patients with TKI-resistant, chronic-phase chronic myeloid leukemia, irrespective of T315I mutation status at baseline, according to findings from the phase 2 OPTIC trial.

Depression, Anxiety Affect Patient Perceptions of Cancer Clinical Trials

December 12th 2021

Depression and anxiety can play a significant role in how patients with cancer view cancer clinical trials, ultimately leading to low enrollment

Active Disease, ICU Deferral Linked With COVID-19–Related Mortality in AML, ALL, and MDS

December 12th 2021

Mortality rates in patients with acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome who were diagnosed with COVID-19 were higher compared with non-cancer populations who were infected with the virus.

Tafasitamab/Lenalidomide Improves OS Over Other Options in Retrospective Relapsed/Refractory DLBCL

December 11th 2021

The combination of tafasitamab and lenalidomide prolonged median overall survival compared with other standard options for autologous stem cell transplant-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma.

Loncastuximab Tesirine/Ibrutinib Combination Elicits Encouraging Activity in Relapsed/Refractory DLBCL

December 11th 2021

Treatment with ibrutinib plus loncastuximab tesirine-lpyl resulted in high objective and complete response rates and an acceptable safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma, according to findings from an interim analysis of the phase 1/2 LOTIS-3 trial (NCT03684694) that were presented at the 2021 ASH Annual Meeting and Exposition.

Dr. Neelapu on Long-Term Follow-Up of ZUMA-5 With Axicabtagene Ciloleucel in R/R Non-Hodgkin Lymphoma

December 11th 2021

Sattva S. Neelapu, MD, discusses the long-term follow-up analysis of the phase 2 ZUMA-5 trial with axicabtagene ciloleucel in patients with relapsed/refractory indolent non-Hodgkin lymphoma. 

Strong Antibody Response to mRNA COVID-19 Vaccine Observed in AML, MDS

December 11th 2021

An observational single-center study suggests that mRNA-1273 SARS CoV-2 vaccination induces a strong antibody response in patients with acute myeloid leukemia and myelodysplastic syndrome, according to observational results presented during the 2021 ASH Annual Meeting.

Daratumumab Plus VTd Enhances MRD-Negativity Rates in Transplant-Eligible Myeloma

December 11th 2021

Minimal residual disease–negativity rates were significantly higher after utilizing daratumumab plus bortezomib, thalidomide, and dexamethasone (VTd) vs VTd alone in patients with newly diagnosed, transplant-eligible multiple myeloma, according to findings from the phase 3 CASSIOPEIA study that were presented at the 2021 ASH Annual Meeting and Exposition.

Subcutaneous Daratumumab Plus SOC Maintains Efficacy in Newly Diagnosed AL Amyloidosis

December 11th 2021

The addition of subcutaneous daratumumab to standard-of-care bortezomib, cyclophosphamide, and dexamethasone (D-VCd) continued to elicit stronger hematologic and organ responses vs VCd alone in patients with newly diagnosed light chain amyloidosis.

Isatuximab Plus RVd Improves MRD Negativity Rates in Transplant-Eligible, Newly Diagnosed Myeloma

December 11th 2021

The addition of isatuximab to lenalidomide, bortezomib, and dexamethasone (RVd) demonstrated superior minimal residual disease rates vs RVd alone when used as induction treatment in patients with transplant-eligible newly diagnosed multiple myeloma.

Tisagenlecleucel Displays Promising Efficacy Results Across Subgroups in R/R FL

December 11th 2021

Tisagenlecleucel produced a high overall response rate and complete response rate in adult patients with relapsed/refractory follicular lymphoma who had received 2 or more prior lines of therapy, according to results from an extended follow-up analysis of patients with at least 12 months of follow-up of the phase 2 ELARA trial.

Axi-Cel Demonstrates Ongoing Survival Benefit in Relapsed/Refractory iNHL

December 11th 2021

Axicabtagene ciloleucel induced high response rates and improved survival in patients with relapsed/refractory follicular lymphoma or marginal zone lymphoma, according to updated data from the phase 2 ZUMA-5 trial.

Daratumumab Plus Talquetamab Demonstrates Tolerable Safety Profile and High Response Rates in R/R Multiple Myeloma

December 11th 2021

Daratumumab plus talquetamab demonstrated a tolerable safety profile and induced responses in more than 75% of patients with relapsed/refractory multiple myeloma across dose levels.

Parsaclisib Elicits Lasting Responses in Relapsed/Refractory Marginal Zone Lymphoma

December 11th 2021

Parsaclisib demonstrated early and long-lasting responses in patients with BTK-naïve, relapsed/refractory marginal zone lymphoma, according to findings from the phase 2 CITADEL-204 trial.

NEXT PAGE
PREVIOUS PAGE
x